ARUP Licenses Ipsogen Leukemia MDx IP | GenomeWeb

NEW YORK (GenomeWeb News) – French molecular diagnostics company Ipsogen has licensed rights to use gene variants for diagnosing leukemia to ARUP Laboratories, a reference lab that is part of the University' of Utah's Department of Pathology.

Under the agreement, ARUP licensed non-exclusive rights to use the group of JAK2 gene variations to screen for myeloproliferative neoplasms (MPN), a group of leukemias, in the US, Ipsogen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.